Itraconazole Dosing for Tinea Capitis
For tinea capitis, itraconazole should be dosed at 50-100 mg per day for 4 weeks, or 5 mg/kg/day for 2-4 weeks, and is recommended as second-line therapy when first-line agents (griseofulvin or terbinafine) have failed. 1
Role in Treatment Algorithm
- Itraconazole is positioned as second-line therapy for tinea capitis, not first-line treatment 1
- First-line agents remain griseofulvin (for Microsporum species) and terbinafine (for Trichophyton species) 1
- Itraconazole has broad-spectrum activity against both Trichophyton and Microsporum species, making it valuable when the causative organism is unknown or when first-line therapy fails 1
Specific Dosing Regimens
Continuous Daily Dosing
- 50-100 mg per day for 4 weeks (weight-based approach for children) 1
- 5 mg/kg/day for 2-4 weeks (more precise pediatric dosing) 1
- This continuous regimen has demonstrated efficacy in clinical studies with 100% cure rates for M. canis infections when given for 4-8 weeks 2
Pulse Therapy Regimens
- 5 mg/kg/day given for 1-week pulses, with 2-3 weeks off between pulses 3, 4
- Typically requires 1-3 pulses depending on disease severity 3, 4
- Mild disease: 1-2 pulses usually sufficient 4
- Moderate disease: 2-3 pulses typically needed 4
- Severe disease: 3 pulses or more may be required 4
- Alternative pulse regimen: 3 mg/kg/day for 1-week pulses has also shown efficacy 5
- Novel high-dose pulse therapy (6-10 mg/kg/day) has been reported effective but requires further validation 6
When to Use Itraconazole
Consider itraconazole in these specific scenarios:
- Treatment failure with griseofulvin or terbinafine after appropriate duration 1
- Lack of clinical improvement despite adequate first-line therapy 1
- When causative organism is unknown and broad-spectrum coverage is needed 1
- If itraconazole was used as first-line (off-guideline), switch to terbinafine for Trichophyton or griseofulvin for Microsporum if it fails 1
Important Caveats and Limitations
Licensing Restrictions
- Not licensed in the UK for children ≤12 years with tinea capitis, though it is licensed in Europe for this indication 1
- Licensed for children >12 years in the UK 1
- Despite lack of pediatric licensing in some regions, it is widely used off-label with established safety data 2, 3, 4
Drug Interactions
- Significant CYP3A4-mediated interactions require careful medication review 1
- Enhanced toxicity with warfarin, certain antihistamines (terfenadine, astemizole), antipsychotics (sertindole), midazolam, digoxin, cisapride, ciclosporin, and simvastatin 1
- Decreased efficacy with H2 blockers, phenytoin, and rifampicin 1
- Contraindicated with multiple medications due to serious interaction potential 7
Absorption Considerations
- Itraconazole oral solution requires fasting administration for optimal absorption 5
- Capsule formulation should be taken with food for better absorption (general medicine knowledge)
- Patients with renal or hepatic impairment may have altered exposure and require dose adjustment 7
Monitoring and Follow-up
- Treatment endpoint is mycological cure, not just clinical improvement 1
- Repeat mycology sampling recommended until clearance achieved 1
- If clinical improvement occurs but mycology remains positive, continue therapy for additional 2-4 weeks 1
- Consider compliance, drug absorption, organism sensitivity, and reinfection if treatment fails 1
Safety Profile
- Generally well-tolerated in children with adverse effects in <5% of patients 2
- Most common side effects: mild gastrointestinal symptoms (stomach ache, diarrhea, nausea) 2, 5, 4
- No laboratory monitoring routinely required unless indicated by history or development of side effects 2
- High compliance rates reported with pulse therapy regimens 4